What are the internal treatment methods for melasma?

Melasma, a common acquired hyperpigmentation disorder characterized by symmetric, brown-to-gray macules on sun-exposed areas—particularly the face—is influenced by multiple factors including ultraviolet radiation, hormonal fluctuations (e.g., pregnancy, oral contraceptive use), genetic predisposition, and possibly oxidative stress. While topical therapies (e.g., hydroquinone, retinoids, corticosteroids, tranexamic acid) and procedural interventions (e.g., chemical peels, low-fluence Q-switched lasers) form the cornerstone of management, “internal regulation” — often referred to in integrative or traditional medicine contexts — aims to address underlying systemic contributors. From an evidence-informed Western medical perspective, internal approaches focus on optimizing physiological balance rather than targeting melasma as a standalone “internal disease.” Key evidence-supported strategies include:

Hormonal evaluation and modulation: In women with new-onset or worsening melasma, assessment for endogenous or exogenous hormonal drivers is essential. Discontinuation or switching of estrogen-progestin contraceptives—especially those with higher estrogenic activity—may lead to gradual improvement. In cases associated with thyroid dysfunction or polycystic ovary syndrome (PCOS), appropriate endocrine management (e.g., levothyroxine for hypothyroidism, metformin or lifestyle intervention for PCOS) may indirectly support pigment stabilization.

Photoprotection from within: While not a substitute for broad-spectrum sunscreen and sun-avoidance behaviors, certain oral antioxidants have demonstrated adjunctive benefits in clinical studies. Oral polypodium leucotomos extract (a fern-derived antioxidant) has shown efficacy in reducing UV-induced melanocyte activation and improving melasma severity when combined with topical therapy. Similarly, oral tranexamic acid—used off-label at low doses (250–500 mg twice daily)—has robust evidence supporting its role in refractory melasma, particularly the mixed or dermal subtypes, likely via inhibition of plasminogen activation and subsequent downstream effects on keratinocyte-melanocyte signaling and vascular permeability.

Nutritional optimization: Deficiencies in vitamin D, folate, B12, and iron have been observed more frequently in individuals with melasma, though causality remains unclear. Correction of documented deficiencies—especially vitamin D insufficiency, which modulates melanogenesis and immune function—may support overall skin health. A balanced, anti-inflammatory diet rich in polyphenols (e.g., berries, green tea, dark leafy vegetables) and omega-3 fatty acids may help mitigate oxidative stress and low-grade inflammation implicated in pigment dysregulation.

Lifestyle and metabolic health: Chronic stress, poor sleep, and insulin resistance are increasingly recognized as potential modifiers of cutaneous inflammation and pigmentary responses. Stress reduction techniques (e.g., mindfulness-based practices), consistent sleep hygiene, and metabolic optimization—including weight management and glycemic control in prediabetes or insulin resistance—may contribute to long-term melasma stability.

It is critical to emphasize that no internal therapy replaces rigorous photoprotection or first-line topical regimens. All systemic interventions—especially oral tranexamic acid—require careful risk-benefit assessment and supervision by a qualified healthcare provider due to potential contraindications (e.g., history of thromboembolism, active malignancy, renal impairment). A personalized, multidisciplinary approach—integrating dermatology, endocrinology, and nutritional counseling when indicated—offers the most effective and sustainable strategy for managing melasma.